ArticleInternational journal of clinical and experimental medicine2015
Influence of dexmedetomidine on incidence of adverse reactions introduced by hemabate in postpartum hemorrhage during cesarean section.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- The Anesthetic Effect and Safety of Dexmedetomidine in Cesarean Section: A Meta-Analysis.BioMed research international · 2022Pooled it
- Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section.The Cochrane database of systematic reviews · 2021Pooled it
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.The Cochrane database of systematic reviews · 2018Pooled it
- Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.The Cochrane database of systematic reviews · 2018Pooled it
- Intravenous dexmedetomidine during spinal anaesthesia for caesarean section: A meta-analysis of randomized trials.The Journal of international medical research · 2017Pooled it
- Effectiveness of Dexmedetomidine and Sufentanil in Preventing Adverse Reactions to Carboprost Tromethamine During Cesarean Section with Noninvasive Cardiac System Monitoring.Clinical drug investigation · 2026Trial
- A Comparison of Dexmedetomidine and Midazolam for the Prevention of Postoperative Nausea and Vomiting Caused by Hemabate in Cesarean Delivery: A Randomized Controlled Trial.Drug design, development and therapy · 2020Trial
- Intrathecal Dexmedetomidine Combined With Ropivacaine in Cesarean Section: A Prospective Randomized Double-Blind Controlled Study.Frontiers in medicine · 2022Article
- The Advantage of Implementation of Enhanced Recovery After Surgery (ERAS) in Acute Pain Management During Elective Cesarean Delivery: A Prospective Randomized Controlled Trial.Therapeutics and clinical risk management · 2020Article
- Remifentanil for Carboprost-Induced Adverse Reactions During Cesarean Delivery Under Combined Spinal-Epidural Anesthesia.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of our study was to observe the influence of dexmedetomidine on complications caused by hemabate in patients undergoing caesarean section.
methodsA total of 120 females (age range, 20-40 years) at 35-40 weeks gestation who delivered by cesarean between September, 2014 and December, 2014 were enrolled in our study. Patients were randomly allocated into three groups that received intravenously physiological saline 20 mL (placebo group), lower dose (0.5 μg kg(-1)) of dexmedetomidine (low-dex gruop) and higher dose (1 μg kg(-1)) of dexmedetomidine (high-dex group) during cesarean section, following the delivery of the infant and intramuscular hemabate injection.
resultsNausea, vomiting, chest congestion and elevated blood pressure were the most common adverse events of placebo group. Compared with placebo group, the above mentioned adverse reactions decreased significantly in both low-dex group and high-dex group (P<0.05), whereas there were no significant difference between low-dex group and high-dex group (P>0.05). As to patient satisfaction score, low-dex group and high-dex group were all higher than placebo group (P<0.05). Furthermore, there were more patients satisfied with high-dex group than low-dex group (P<0.05).
conclusionDexmedetomidine (0.5 μg kg(-1) and 1 μg kg(-1)) were all effective in preventing adverse reactions introduced by hemabate and improve parturients' satisfaction in patients undergoing cesarean delivery. And higher dose (1 μg kg(-1)) of dexmedetomidine is superior to lower dose (0.5 μg kg(-1)) in patient satisfaction.
Indexed as
Identifiers
26550325PMC4613010W2417138833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.